Инновации по диагностике и лечению пациентов с гипертриглицеридемиями

Аннотация

В статье представлен обзор инновационных технологий по диагностике пациентов с гипертриглицеридемиями. Отмечено, что гипертриглицеридемия является не только независимым фактором 10-летнего риска смерти от сердечно-сосудистых заболеваний, но и при ее высоком уровне причиной развития острого панкреатита. Отражены современные принципы стратификации риска у пациентов с гипертриглицеридемиями и их фармакотерапии.

Список литературы

1. Shi Y, Cheng D. Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism. Am J Physiol Endocrinol Metab. 2009;297(1):E10–8. doi:  10.1152/ajpendo.90949.2008

2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo controlled trial THE LANCET. Vol 360. July 6, 2002.  www.thelancet.com

3. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010;375:1634–1639. doi: 10.1016/S0140-6736(10)60545-4.

4. Chapman MJGinsberg HNAmarenco PAndreotti FBorén JCatapano ALDescamps OSFisher EKovanen PTKuivenhoven JALesnik PMasana LNordestgaard BGRay KKReiner ZTaskinen MRTokgözoglu LTybjærg-Hansen AWatts GF;, and the European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345–61. doi: 10.1093/eurheartj/ehr112. Epub 2011 Apr 29.

5. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011;13 (6):544–52. doi: 10.1007/s11886-011-0220-3.

6. Brahm A, Hegele RA. Hypertriglyceridemia. Nutrients. 2013;5(3):981–1001. doi:10.3390/nu5030981

7. Robert A Hegele, Henry N Ginsberg, M John Chapman, Børge G Nordestgaard, Jan Albert Kuivenhoven, Maurizio Averna, Jan Borén, Eric Bruckert, Alberico L Catapano, Olivier S Descamps, G Kees Hovingh, Steve E Humphries, Petri T Kovanen, Luis Masana, Päivi Pajukanta, Klaus G Parhofer, Frederick J Raal, Kausik K Ray, Raul D Santos, Anton F H Stalenhoef, Erik Stroes, Marja-Riitta Taskinen, Anne Tybjærg‑Hansen, Gerald F Watts, Olov Wiklund. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. Lancet Diabetes Endocrinol 2014;(2):655–666. www.thelancet.com/diabetes-endocrinology. doi: 10.1016/S2213-8587(13)70191-8

8. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;(285):2486–97.

9. Catapano ALReiner ZDe Backer GGraham ITaskinen MRWiklund OAgewall SAlegria EChapman MJDurrington PErdine SHalcox JHobbs RKjekshus JPerrone Filardi PRiccardi GStorey RFWood D. Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), and the ESC Committee for Practice Guidelines 2008–2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217 (suppl 1): S1–44). DOI:10.1016/j.atherosclerosis.2011.06.012

10. Berglund LBrunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MHStalenhoef AF. Endocrine Society. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2012; 97: 2969–89.doi:10.1210/jc.2011-3213

11. Sarwar NDanesh JEiriksdottir GSigurdsson GWareham NBingham SBoekholdt SMKhaw KTGudnason V.Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262 525 participants in 29 Western prospective studies. Circulation 2007; 115: 450–58.

12. Sarwar N, Sattar N. Triglycerides and coronary heart disease: have recent insights yielded conclusive answers? Curr Opin Lipidol 2009; 20: 275–81.doi: 10.1097/MOL.0b013e32832dd4dc.

13. Morrison A, Hokanson JE. The independent relationship between triglycerides and coronary heart disease. Vasc Health Risk Manag. 2009;5(1):89-95. E-pub 2009 Apr 8.

14. Austin MA, Hokanson JE, Edwards KL Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B–12B.

15. Yuan G, Al-Shali KZ, Hegele RA. Hypertriglyceridemia: its etiology, effects and treatment. CMAJ, 2007, 176: 1113–20.

16. Reiner Z, Catapano ALDe Backer GGraham ITaskinen MRWiklund OAgewall SAlegria EChapman MJDurrington PErdine SHalcox JHobbs RKjekshus JFilardi PPRiccardi GStorey RFWood D, and the European Association for Cardiovascular Prevention & Rehabilitation, and the ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011, 32: 1769–818. doi: 10.1093/eurheartj/ehr158.

17. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA, 2007; 298: 299–308.

18. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Nonfasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008300: 2142–52.doi: 10.1001/jama.2008.621

19. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyørølø K, Keil U; EUROASPIRE Study Group. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;(16):121–137.

20. Bansal S1, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA. 2007 Jul 18;298(3):309-16.

21. The ACCORD Study Group. Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus. N Engl J Med 2010. Published on March 14, 2010, updated on March 18, 2010, at NEJM.org. DOI: 10.1056/NEJMoa1001282

22. Assmann G, MD, FRCP; Cullen P, MD, FRCPI; Schulte H, PhD. Simple Scoring Scheme for Calculating the Risk of Acute Coronary Events Based on the 10-Year Follow-Up of the Prospective Cardiovascular Münster (PROCAM) Study. Downloaded from http://circ.ahajournals.org/ Downloaded from/ by guest on January 4, 2017.

23. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Emerging Risk Factors Collaboration. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009 Nov 11;302(18):1993-2000. PubMed PMID: 19903920.  doi: 10.1001/jama.2009.1619.

24. Varbo A, Benn M, Tybjørg-Hansen A, Jørgensen AB, Frikke Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. J Am Coll Cardiol 2013; 61: 427–36. doi: 10.1016/j.jacc.2012.08.1026

25. Jørgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjærg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. Eur Heart J 2013; 34: 1826–33. doi:10.1093/eurheartj/ehs431

26. Anderson TJGrégoire JHegele RACouture PMancini GBMcPherson RFrancis GAPoirier PLau DCGrover SGenest J JrCarpentier ACDufour RGupta MWard RLeiter LALonn ENg DSPearson GJYates GMStone JAUr E. 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013; 29: 151–67. doi: 10.1016/j.cjca.2012.11.032.

27. NIH-NCEP. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Executive Summary. 2004; NIH. Nugent AP. LIPGENE: an EU project to tackle the metabolic syndrome. Biochimie. 2005;87(1):129–32.

28. Кухарчук В.В., Коновалов Г.А., Галявич А.С. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации пересмотр. М., 2012.

29. Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering effi cacy of ezetimibe plus statin and statin monotherapy and identifi cation of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. Atherosclerosis 2012; 223: 251–61.

30. Baigent CKeech AKearney PMBlackwell LBuck GPollicino CKirby ASourjina TPeto RCollins RSimes R, and the Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–78.

31. Boekholdt SMArsenault BJMora SPedersen TRLaRosa JCNestel PJSimes RJDurrington PHitman GAWelch KMDeMicco DAZwinderman AHClearfield MBDowns JRTonkin AMColhoun HMGotto AM JrRidker PMKastelein JJ.Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012; 307: 1302–09. doi: 10.1001/jama.2012.366

32. Sniderman ADWilliams KContois JHMonroe HMMcQueen MJde Graaf JFurberg CD. A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc Qual Outcomes 2011; 4: 337–45. doi: 10.1161/CIRCOUTCOMES.110.959247.

33. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fruchart JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98: 2088–93.

34. Michos E. D., C. T. Sibley, J. T. Baer, M. J. Blaha, R. S. Blumenthal. Niacin and statin combination therapy for atherosclerosis regression and prevention of cardiovascular disease events: reconciling the AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial with previous surrogate endpoint trials. J Am Coll Cardiol, 59 (2012): 2058–2064.

35. Kamanna V.S., Kashyap M.L. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents? Am J Cardiol 2007(100):53-61.

36. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360–381.

37. Boden WEProbstfield JLAnderson TChaitman BRDesvignes-Nickens PKoprowicz KMcBride RTeo KWeintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255–2267.  doi: 10.1056/NEJMoa1107579

38. Guyton JRSlee AEAnderson TFleg JLGoldberg RBKashyap MLMarcovina SMNash SDO'Brien KDWeintraub WSXu PZhao XQBoden WE. Relationship of lipoproteins to cardiovascular events in the atherothrombosis intervention in metabolic syndrome with low HDL/high triglycerides and impact on global health outcomes (AIM-HIGH) trial. J Am Coll Cardiol 2013;62(17):1580–1584. doi: 10.1016/j.jacc.2013.07.023.

39. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34(17):1279–1291).

40. Gotoda T, Shirai K, Ohta T, Kobayashi J, Yokoyama S, Oikawa S, Bujo H, Ishibashi S, Arai H, Yamashita S, Harada-Shiba M, Eto M, Hayashi T, Sone H, Suzuki H, Yamada N; Research Committee for Primary Hyperlipidemia. Diagnosis and management of type I and type V hyperlipoproteinemia. J Atheroscler Thromb. 2012; 19 (1):1–12.

41. HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J 2013;34(17):1279–1291.

42. University of Oxford Clinical Trial Service Unit and Epidemiological Studies Unit. HPS2-THRIVE. http://www.ctsu.ox.ac.uk/research/mega-trials/hps2-thrive (accessed Nov 28, 2013).

43. Huijgen RAbbink EJBruckert EStalenhoef AFImholz BPDurrington PNTrip MDEriksson MVisseren FLSchaefer JRKastelein JJ, and the Triple Study Group. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12‑week, multicenter, randomized, double-blind, controlled trial. Clin Ther 2010; 32: 615–25. doi: 10.1016/j.clinthera.

44. Erik S. Stroes;  Paul D. Thompson;  Alberto Corsini;  Georgirene D. Vladutiu; Frederick J. Raal;  Kausik K. Ray;  Michael Roden;  Evan Stein;  Lale Tokgözoğlu; Børge G. Nordestgaard;  Eric Bruckert;  Guy De Backer;  Ronald M. Krauss; Ulrich Laufs;  Raul D. Santos;  Robert A. Hegele;  G. Kees Hovingh; Lawrence A. Leiter;  Francois Mach;  Winfried März;  Connie B. Newman; Olov Wiklund;  Terry A. Jacobson;  Alberico L. Catapano;  M. John Chapman; Henry N. Ginsberg European Atherosclerosis Society Consensus Panel; European Atherosclerosis Society Consensus Panel;  Erik Stroes; Paul D. Thompson;  Alberto Corsini;  Georgirene D. Vladutiu;  Frederick J. Raal; Kausik K. Ray;  Michael Roden;  Evan Stein;  Lale Tokgözoğlu; Børge G. Nordestgaard;  Eric Bruckert;  Ronald M. Krauss;  Ulrich Laufs; Raul D. Santos;  Winfried März;  Connie B. Newman;  M. John Chapman; Henry N. Ginsberg;  M. John Chapman;  Henry N. Ginsberg; Guy de Backer; Alberico L. Catapano;  Robert A. Hegele;  G. Kees Hovingh;  Terry A. Jacobson; Lawrence Leiter;  Francois Mach  Olov Wiklund. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J (2015) 36 (17): 1012-1022. DOI: https://doi.org/10.1093/eurheartj/ehv043

45. Brunzell JD, Miller NE, Alaupovic P, Hilaire R.J.St, Wang C.S,  David L. hn, Bloom SR, and Lewis B. Familial chylomicronemia due to a circulating inhibitor of lipoprotein lipase activity. Journal of Lipid Research. 1983;24(1):12–19.

46. Santamarina-Fojo S. The familial chylomicronemia syndrome. Endocrinology and Metabolism Clinics of North America. 1998; 27 (3):551–567.

47. Leaf DA. Chylomicronemia and the chylomicronemia syndrome: a practical approach to management. Am J Med. 2008; 121 (1): 10–2. doi: 10.1016/j.amjmed

48. Gaddi A, Cicero AF, Odoo FO, Poli AA, Paoletti R; Atherosclerosis and Metabolic Diseases Study Group. Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date. Vasc Health Risk Manag. 2007;3(6):877–86.

49. Gotoda T, Shirai K, Ohta T, Kobayashi J, Yokoyama S, Oikawa S, Bujo H, Ishibashi S, Arai H, Yamashita S, Harada-Shiba M, Eto M, Hayashi T, Sone H, Suzuki H, Yamada N. Research Committee for Primary Hyperlipidemia. Diagnosis and management of type I and type V hyperlipoproteinemia. JAtherosclerThromb. 2012; 19(1):1–12.

Для цитирования

Симерзин В.В., Фатенков О.В., Гаглоева И.В., Галкина М.А., Панишева Я.А., Красовская М.А. Инновации в диагностике и лечении пациентов с гипертриглицеридемиями. Наука и инновации в медицине. 2017;1(5):43-51.

Заявка

Отправьте онлайн-заявку на публикацию

Оформить